Selecta Biosciences Company Profile (NASDAQ:SELB)

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Selecta Biosciences, Inc. (NASDAQ:SELB) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.85) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.86) by $0.01. The company had revenue of $0.03 million for the quarter. Selecta Biosciences had a negative net margin of 1,277.76% and a negative return on equity of 88.31%. View Selecta Biosciences' Earnings History.

Selecta Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Selecta Biosciences.

3 analysts have issued twelve-month target prices for Selecta Biosciences' shares. Their forecasts range from $25.00 to $32.00. On average, they anticipate Selecta Biosciences' stock price to reach $28.33 in the next year. View Analyst Ratings for Selecta Biosciences.

Here are some recent quotes from research analysts about Selecta Biosciences stock:

• 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (8/16/2017)
• 2. Canaccord Genuity analysts commented, "We are particularly interested in data on antibodies to SEL-212, which we expect to be very clean; that is, we do not expect antibodies to SEL-212. Given the previous data that we have seen, we are expecting SEL-212 to continue positive development with strong ADA suppression and a highly tolerable safety profile." (8/11/2017)
• 3. Needham & Company LLC analysts commented, "Selecta presented initial Phase II multi-dose data for SEL-212 on its 4Q16 earnings call. We believe this early data is very encouraging as a clinically active monthly dose appears to have been reached. Dosing continues with 2 additional cohorts. The next update is expected at a conference in June. We remain buyers of SELB as we believe they have both a promising clinical candidate in SEL-212 and a broadly applicable platform to induce tolerance to anti-drug antibodies." (3/28/2017)

Some companies that are related to Selecta Biosciences include Aduro Biotech (ADRO), Reata Pharmaceuticals (RETA), Cytokinetics, Incorporated (CYTK), Revance Therapeutics (RVNC), La Jolla Pharmaceutical Company (LJPC), Audentes Therapeutics (BOLD), AnaptysBio (ANAB), Alder BioPharmaceuticals (ALDR), G1 THERAPEUTICS (GTHX), Versartis (VSAR), Ignyta (RXDX), Achaogen (AKAO), Aclaris Therapeutics (ACRS), Paratek Pharmaceuticals (PRTK), Coherus BioSciences (CHRS), CytomX Therapeutics (CTMX), Insys Therapeutics (INSY) and MacroGenics (MGNX).

Selecta Biosciences' management team includes the folowing people:

• Werner Cautreels Ph.D., Chairman of the Board, President, Chief Executive Officer
• Omid Farokhzad M.D., Co-Founder, Director
• David Siewers, Chief Financial Officer, Treasurer
• Lloyd Johnston Ph.D., Chief Operating Officer, Senior Vice President - Research & development
• Takashi Kei Kishimoto Ph.D., Chief Scientific Officer
• David Abraham J.D., Chief Compliance Officer, General Counsel, Corporate Secretary
• Peter Keller, Chief Business Officer
• Dmitry Ovchinnikov, Managing Director, SelectaRUS, LLC
• Earl Sands M.D., Chief Medical Officer
• Carl L. Gordon Ph.D., Director

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Selecta Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (5.91%), JPMorgan Chase & Co. (0.00%), FMR LLC (0.00%), Sphera Funds Management LTD. (0.00%), Vanguard Group Inc. (0.00%) and State Street Corp (0.00%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, David Siewers, Edwin M Kania, Jr, Lloyd P Johnston, Nanodimension Management Ltd, Peter Keller, Takashi Kei Kishimoto and Timothy A Springer. View Institutional Ownership Trends for Selecta Biosciences.

Selecta Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Vanguard Group Inc., JPMorgan Chase & Co., Candriam Luxembourg S.C.A., State Street Corp, Northern Trust Corp, Wasatch Advisors Inc. and TIAA CREF Investment Management LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Nanodimension Management Ltd and Timothy A Springer. View Insider Buying and Selling for Selecta Biosciences.

Shares of Selecta Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Selecta Biosciences stock can currently be purchased for approximately $20.03.